AVBP•benzinga•
ArriVent BioPharma 2024 Net Loss $80.5M; Cash, Cash Equivalent And Investments Of $266.5M As Of Dec. 31, 2024
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 3, 2025 by benzinga